GTHX (G1 Therapeutics, Inc.) צמיחת רווח נקי למניה השנה

Geopolitical instability is limiting the export of oncology drugs and access to raw materials, which is confirmed by the comparison of annual EPS growth, where the latest parameter stands at 59.20. G1 Therapeutics, Inc. (GTHX) revenues are based on the sale of COSELA for bone marrow protection. Management's current course toward increasing royalty payments creates a foundation for further growth in earnings per share.
פילוחי מדדים פיננסיים ומדדי שוק עבור G1 Therapeutics Inc. (GTHX)

G1 Therapeutics, Inc. (GTHX) develops specialized oncology drugs, integrating strict ESG standards and environmental optimization into its production cycles. By analyzing the annual dynamics of net income per share, an investor can see the impact of these operating expenses on the business's real yield in real-time. This indicator measures the rate of change in EPS relative to the previous year, allowing one to detect a trend reversal in time and avoid purchasing an overvalued asset.